Research programme: cancer therapeutics - Endo/Jubilant
Alternative Names: CYP17A1 inhibitor - Endo/Jubilant; EN-3356Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Endo Pharmaceuticals; Jubilant Biosys
- Class Small molecules
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in India
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in India (PO)